electroCore to Announce First Quarter March 31, 2026, Financial Results on Wednesday, May 6, 2026
Rhea-AI Summary
electroCore (Nasdaq: ECOR) will report first-quarter financial results for the period ended March 31, 2026, after market close on Wednesday, May 6, 2026.
Management will host a webinar at 4:30 PM EDT to review results and answer questions; investors may join by dial-in or registration (webinar ID and passcode provided).
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – ECOR
On the day this news was published, ECOR declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Before this earnings-date news, ECOR was up 1.32% with light volume. Momentum scanners showed peers IINN and MODD up 3.77% and 9.05% respectively, but overall sector movement was flagged as stock-specific, not a coordinated sector move.
Previous Earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 09 | Earnings date notice | Neutral | -3.1% | Announced Q4 and full-year 2025 results date and investor webinar logistics. |
Prior earnings-date scheduling news coincided with a modest negative price reaction of -3.07% the next day.
Over recent months, electroCore has issued multiple operational and clinical updates, including PTSD and mTBI nVNS data, new executive hires with equity awards, and participation in investor conferences. For the specific earnings date tag, the only prior event on Mar 09, 2026 announced the timing of Q4 and full-year 2025 results and a 4:30 PM EDT webinar. That announcement saw a -3.07% next-day move, suggesting earnings-date notices have not been clear upside catalysts historically.
Historical Comparison
In the past 6 months, ECOR has issued 1 prior earnings-date notice, with an average next-day move of -3.07%. This context frames how scheduling announcements have historically been received.
Earnings communications have followed a consistent pattern of pre-announcing release dates and 4:30 PM EDT webinars for results discussion.
Regulatory & Risk Context
An effective resale registration filed on Oct 03, 2025 covers up to 762,508 common shares held by selling stockholders. The company is not issuing new securities under this filing and receives no proceeds from these resales, though additional stockholder selling could still influence trading dynamics.
Market Pulse Summary
This announcement schedules the Q1 2026 earnings release for May 6, 2026 and a 4:30 PM EDT webinar, giving the market a clear timetable for updated financials and guidance. Historical context shows one prior earnings-date notice with a modest negative reaction of -3.07%. Investors may focus on revenue growth, margins, cash levels, and any updates to 2026 outlook or strategic initiatives when the full results are reported.
AI-generated analysis. Not financial advice.
ROCKAWAY, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the first quarter ended March 31, 2026, after the close of the market on Wednesday, May 6, 2026.
Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the details below:
Wednesday, May 6, 4:30 PM EDT
Dial-In: (646) 931-3860
Webinar ID: 856 5438 2775
Passcode: 895430
Registration Link: Click here to participate and ask questions on the call.
About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
